Wed, November 1, 2017
Tue, October 31, 2017
Mon, October 30, 2017
Fri, October 27, 2017
Thu, October 26, 2017
Wed, October 25, 2017

M. Ian Somaiya Maintained (BMRN) at Buy with Increased Target to $119 on, Oct 27th, 2017


//stocks-investing.news-articles.net/content/201 .. th-increased-target-to-119-on-oct-27th-2017.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


M. Ian Somaiya of BMO Capital, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $117 to $119 on, Oct 27th, 2017.

M. has made no other calls on BMRN in the last 4 months.



There are 7 other peers that have a rating on BMRN. Out of the 7 peers that are also analyzing BMRN, 2 agree with M.'s Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Kennen MacKay of "RBC Capital" Initiated at Hold and Held Target at $93 on, Friday, September 15th, 2017
  • Vincent Chen of "Bernstein" Initiated at Hold and Held Target at $89 on, Thursday, July 27th, 2017


These are the ratings of the 5 analyists that currently disagree with M.


  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $124 on, Thursday, October 19th, 2017
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $142 on, Thursday, October 19th, 2017
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $117 on, Friday, October 6th, 2017
  • Christopher Raymond of "Piper Sandler" Initiated at Buy on, Thursday, September 14th, 2017
  • Josh Schimmer of "Evercore ISI Group" Initiated at Buy on, Thursday, August 17th, 2017

Publication Contributing Sources